1ST Source Bank decreased its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 1.1% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 24,786 shares of the medical research company’s stock after selling 288 shares during the period. 1ST Source Bank’s holdings in Thermo Fisher Scientific were worth $4,325,000 at the end of the most recent reporting period.

A number of other large investors have also bought and sold shares of the company. Proficio Capital Partners LLC increased its stake in shares of Thermo Fisher Scientific by 71.5% in the first quarter. Proficio Capital Partners LLC now owns 607 shares of the medical research company’s stock valued at $105,000 after buying an additional 253 shares in the last quarter. Cribstone Capital Management LLC increased its stake in shares of Thermo Fisher Scientific by 8.7% in the second quarter. Cribstone Capital Management LLC now owns 625 shares of the medical research company’s stock valued at $109,000 after buying an additional 50 shares in the last quarter. CWM LLC increased its stake in shares of Thermo Fisher Scientific by 17.0% in the second quarter. CWM LLC now owns 710 shares of the medical research company’s stock valued at $124,000 after buying an additional 103 shares in the last quarter. Independent Portfolio Consultants Inc. increased its stake in shares of Thermo Fisher Scientific by 0.3% in the first quarter. Independent Portfolio Consultants Inc. now owns 730 shares of the medical research company’s stock valued at $112,000 after buying an additional 2 shares in the last quarter. Finally, Sharkey Howes & Javer increased its stake in shares of Thermo Fisher Scientific by 1.0% in the first quarter. Sharkey Howes & Javer now owns 733 shares of the medical research company’s stock valued at $113,000 after buying an additional 7 shares in the last quarter. Hedge funds and other institutional investors own 87.60% of the company’s stock.

Shares of Thermo Fisher Scientific Inc. (TMO) opened at 175.81 on Thursday. Thermo Fisher Scientific Inc. has a 52 week low of $139.07 and a 52 week high of $182.87. The stock has a 50 day moving average price of $176.74 and a 200-day moving average price of $167.17. The company has a market capitalization of $68.59 billion, a PE ratio of 30.63 and a beta of 1.06.

Thermo Fisher Scientific (NYSE:TMO) last issued its earnings results on Wednesday, July 26th. The medical research company reported $2.30 earnings per share for the quarter, beating the consensus estimate of $2.27 by $0.03. The company had revenue of $5 billion during the quarter, compared to analysts’ expectations of $4.92 billion. Thermo Fisher Scientific had a return on equity of 11.11% and a net margin of 12.27%. Thermo Fisher Scientific’s quarterly revenue was up 10.2% compared to the same quarter last year. During the same period in the prior year, the business posted $2.03 EPS. Equities research analysts expect that Thermo Fisher Scientific Inc. will post $9.24 EPS for the current year.

The business also recently announced a quarterly dividend, which will be paid on Monday, October 16th. Investors of record on Friday, September 15th will be issued a dividend of $0.15 per share. This represents a $0.60 annualized dividend and a yield of 0.34%. The ex-dividend date is Thursday, September 14th. Thermo Fisher Scientific’s dividend payout ratio is presently 10.45%.

COPYRIGHT VIOLATION NOTICE: This article was reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this article on another website, it was stolen and republished in violation of U.S. & international copyright & trademark legislation. The legal version of this article can be accessed at https://www.thecerbatgem.com/2017/08/24/1st-source-bank-sells-288-shares-of-thermo-fisher-scientific-inc-tmo.html.

TMO has been the topic of several recent analyst reports. Bank of America Corporation restated a “buy” rating and issued a $210.00 target price (up previously from $200.00) on shares of Thermo Fisher Scientific in a research note on Friday, July 21st. Zacks Investment Research downgraded shares of Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a research note on Monday, July 31st. Barclays PLC set a $175.00 target price on shares of Thermo Fisher Scientific and gave the company a “buy” rating in a research note on Wednesday, April 26th. Cantor Fitzgerald initiated coverage on shares of Thermo Fisher Scientific in a research note on Thursday, May 18th. They issued an “overweight” rating and a $194.00 target price on the stock. Finally, Cowen and Company restated an “outperform” rating and issued a $185.00 target price (up previously from $175.00) on shares of Thermo Fisher Scientific in a research note on Saturday, April 29th. One investment analyst has rated the stock with a hold rating, seventeen have issued a buy rating and one has given a strong buy rating to the stock. The company presently has an average rating of “Buy” and an average price target of $188.56.

In related news, CEO Marc N. Casper sold 20,000 shares of the stock in a transaction dated Thursday, June 1st. The stock was sold at an average price of $172.79, for a total transaction of $3,455,800.00. Following the completion of the sale, the chief executive officer now directly owns 269,279 shares in the company, valued at approximately $46,528,718.41. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Stephen Williamson sold 2,500 shares of the stock in a transaction dated Monday, June 5th. The shares were sold at an average price of $176.26, for a total value of $440,650.00. Following the sale, the chief financial officer now owns 37,790 shares of the company’s stock, valued at $6,660,865.40. The disclosure for this sale can be found here. Insiders have sold a total of 34,818 shares of company stock valued at $6,028,985 over the last 90 days. 0.49% of the stock is currently owned by company insiders.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Stock Ratings for Thermo Fisher Scientific Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific Inc. and related stocks with our FREE daily email newsletter.